Hypera® is an unregistered prescription medicine (S8) and therefore does not have registered therapeutic indications. However, benefits from tetrahydrocannabinol have been demonstrated in conditions such as (but not limited to) insomnia, lack of appetite, nausea and vomiting, pain and anxiety disorders.
|Price per mg of cannabinoid||$0.19|
|Country of Origin||United States|
Dosing needs to be individually titrated for each patient. The general rule is to “start low and go slow” to maximize therapeutic benefit and minimize adverse effects. It may take days to weeks to obtain an optimal individualised dose of Hypera®.